ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: A case is described of a chronic-phase CML patient who achieved a sustained, deep molecular response but who developed an Y253H <i>ABL1</i> kinase domain mutation nearly nine years after commencing imatinib.